Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences
POINT RICHMOND, Calif., May 9, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at two upcoming investor conferences.
Transcept management plans to present a general corporate overview at the:
JMP Securities Research Conference in San Francisco on May 15, 2012, 6:30 p.m. ET; and
Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 17, 2012, 1:40 p.m. ET.
A live audio webcast of each presentation will be available in the investor relations section of the Transcept website at www.transcept.com. The archive of the presentation will be available there for approximately 30 days following the event.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.
Transcept Pharmaceuticals, Inc.
Senior Director, Corporate Communications
SOURCE Transcept Pharmaceuticals, Inc.
More by this Source
Transcept Pharmaceuticals Statement on Dismissal of Derivative Lawsuit
Jan 13, 2014, 18:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.